PTC Therapeutics, Inc. PTCT
Analyst Ratings
- Consensus
- Moderate Buy — 8 Buy · 1 Hold · 1 Sell (10 analysts)
- Avg. Price Target
- $97.60 (+36.1% upside)
Key Stats
- Today's Range
- $70.85 – $72.13
- 50-Day Range
- $64.57 – $90.87
- 52-Week Range
- $43.17 – $90.87
- Volume
- 564K shs
- Average Volume
- 1.32 million shs
- Market Cap
- $5.98 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- -36.19
- Price / Sales
- 5.93
Short Interest
- Short Interest
- 7.88%
- Days to Cover
- 15.48
Financials (TTM)
- Revenue
- $1.01 billion
- Net Income
- $-38,382,000
- Net Margin
- -3.80%
- Return on Equity
- 23.21%
- Debt-to-Equity
- —
About PTC Therapeutics, Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Related Stocks
Compare head-to-head: PTCT vs LLY·PTCT vs JNJ·PTCT vs ABBV·PTCT vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.